Target Audience: Infectious Disease Specialists, Epidemiologists, and Clinical Practitioners.
Abstract:
This clinical update provides a comprehensive review of the current respiratory virus landscape and significant recent findings in virology and public health as of March 2026. The session covers the declining trends of Influenza and RSV, while highlighting a late-season surge in Measles and the evolving genotype dominance of Norovirus (GII.17). Key policy updates include the dissolution and restructuring of the Advisory Committee on Immunization Practices (ACIP) following judicial intervention.
The update synthesizes several critical peer-reviewed studies. In bovine health, the rationale for H5N1 vaccination in dairy cattle is examined alongside concerns regarding "sterilizing immunity." Human clinical data discussed includes a large-scale Ontario study debunking the "sudden death" vaccine myth—finding instead a 43% reduction in sudden cardiac death among the vaccinated. Further research confirms the lack of anti-inflammatory benefit for Azithromycin in viral respiratory infections, noting its rapid negative impact on the microbiome. Additionally, new Phase 3b data supports the expansion of RSV vaccination to high-risk adults aged 18–49, and longitudinal data from Norway confirms maternal COVID-19 vaccination provides significant neonatal protection for up to six months. The session concludes with a review of neurocognitive Long COVID interventions and a recommendation for bi-annual COVID-19 boosters for seniors.
Clinical Update: Respiratory Trends, Vaccine Efficacy, and Pathogen Evolution
0:04:53 ACIP Policy Shift: The federal vaccine advisory panel (ACIP) underwent significant changes following a judicial ruling that disbanded the previous iteration; current directives mandate the panel be reconstituted strictly with subject-matter experts.
0:09:03 H5N1 in Livestock: Discussion of a Journal of Infectious Diseases perspective emphasizes the economic and pandemic rationale for vaccinating dairy cattle. Experts debate the feasibility of "sterilizing immunity" in cattle to prevent asymptomatic shedding into the milk supply.
0:12:51 Avian Flu Impact: Significant poultry losses continue, with over 10 million birds depopulated in Indiana alone since 2022. The persistence of the virus suggests a permanent environmental shift.
0:13:35 Raw Milk Pathogens: A Shiga toxin-producing E. coli (STEC) outbreak in Tennessee, linked to raw milk consumption, highlights the ongoing public health risks of unpasteurized dairy, leading to severe pediatric Hemolytic Uremic Syndrome (HUS).
0:15:18 Norovirus Genotype Shift: Longitudinal data shows genotype GII.17 has largely replaced GII.4 as the dominant strain in the U.S. (comprising 75% of cases). Diagnostic alert: Some clinical laboratories have erroneously removed norovirus from standard GI PCR panels, necessitating specific re-ordering.
0:17:30 Measles Resurgence: Confirmed U.S. cases have reached nearly 1,500 by late March, putting the country on track for a high-incidence year (potentially 5,000+ cases) if current trends persist.
0:20:02 RSV Vaccine Expansion: A Phase 3b trial published in CID demonstrates immunological non-inferiority for the RSV pre-F3 vaccine in adults aged 18–49 at high risk compared to those 60+, supporting expanded clinical indications.
0:23:36 COVID-19 and Sudden Death Data: A population-based study in PLOS Medicine of ~5,000 sudden death cases found that COVID-19 vaccination is associated with a 43% reduction in sudden cardiac death risk, particularly in individuals under 40.
0:29:40 Mortality Undercounting: Machine learning analysis of death certificates suggests U.S. COVID-19 deaths were underreported by approximately 19%, with disparities concentrated in rural and minority populations.
0:32:11 Azithromycin Misuse: Research in Nature Microbiology confirms that empiric Azithromycin provides zero anti-inflammatory benefit in COVID-19 but causes rapid (within 24 hours) and persistent increases in antibiotic-resistant gene expression in the respiratory microbiome.
0:35:09 Maternal Vaccination Benefits: A Norwegian registry study confirms that infants born to mothers vaccinated during pregnancy have a 50% lower risk of COVID-19 hospitalization for the first two months of life, with protection waning by six months.
0:36:24 Long COVID Neurocognitive Recovery: A longitudinal study indicates significant improvement in "brain fog" and fatigue using a combination of symptom-titrated physical rehab and pharmacotherapy (Amantadine, Memantine, and Trazodone).
0:48:23 Booster Cadence for Seniors: For adults 65+ and the immunocompromised, a six-month vaccination cycle (October and June) is recommended to align with the biannual surges of COVID-19.